The document discusses test results from multiple trials over several years related to drug development and sales. It provides data on prescription volumes and sales from 2003 to 2007, including a decrease in prescriptions for four drugs ranging from 33% to 37% from 2003 to 2006. Charts show concentrations of two drugs over time and the breakdown of patients by symptomatic and asymptomatic categories.

1. CC Rosario

2. Foundation First steps 2 nd Level Knowledge Next level steps Top Level Results 3 rd Level Two Execution 3 rd Level One Implementation

3. 0 1,000 2,000 3,000 4,000 5,000 6,000 Q2 97 Q2 98 Q2 99 Q2 00 Q2 01 Test One Test Two Branded Generic 0 500 1,000 1,500 2,000 2,500 Q1 96 Q1 97 Q1 98 Q1 99 Q1 00 Q1 01 Test One Test Two Other Versions

6. Source: Safer NSAID

7. Reduction volume Volume Volume 2003 Volume 2006 % Change One 6,254 3,264 -33% Two 5,355 3,356 -37% Three 1,895 1,204 -36% Four 1,107 726 -34%

8. Source: Sales *Through May 2007 2003 2004 2005 2006 2007* 0 20 40 60 80 Total Prescriptions (millions) Trial 2 Continues to Shrink U.S. Prescriptions Sales 2004 $2.3 Billion (+4%) 2005 $1.4 Billion (-41%) 2006 $1.5 Billion (+8%) YTD (Sept 07) $1.1 Billion (+6%) Other Sales YTD (Sept 07) $5.9 Billion (+6%) Trial 1 Trial 2

9. Core 500mg pH-Sensitive Coat Immediate Release (IR) Drug One 15 mg Drug Two 20 mg “ The major point . Secondary point” — Speaker

10. 5 Drug 1 Concentration Drug 2 Concentration Time (hrs) 0 2 4 6 8 10 12 0 50 100 150 200 250 300 350 20 25 30 35 40 45 50 15 0 10

11. 26M 70% Asymptomatic Patients 71M 100M 30% Symptomatic Patients

12. Generic Impact Future Competition 2013-2015 PHASE 2 Sample 1 Landscape 2014 2015 2013 2012 2011 2010 Changes in Scientific Environment Precision Trial Maximum potential for the brand Sample 5 Sample 2 Sample 4 2014 Generics hit the market

13. Point 4 Point 3 Point 2 Point 1 Point 5